Dr Mark Dowling
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
88 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
DOI: 10.1182/blood.20250323072026
Journal article
DEVELOPMENT AND CLINICAL DELIVERY OF AN AUSTRALIAN-MANUFACTURED CD19 CAR-T CELL THERAPY: THE PLATYPS STUDY
DOI: 10.1016/j.jcyt.2026.1026472026
Journal article
Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
DOI: 10.1080/10428194.2025.25797212026
Journal article
Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDS
DOI: 10.1038/s41409-026-02874-52026
Research grants (other domestic)
Development of a Novel Nanobody-Secreting CAR-T Cell for the Treatment of Multiple Myeloma
2025
Research grants (other domestic)
Clinical, Laboratory and Radiological Predictive Factors for Safety and Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Australia: A Multi-Centre Real-World Study
2022
Research grants (other domestic)
Adjuvant Immunotherapy to Improve the Efficacy, Durability, and Cost Effectiveness of CAR T-Cell Therapy for Aggressive Lymphoma
RECENT SCHOLARLY WORKS
2026
Journal article
Neurological implications of chimeric antigen receptor-T cell therapy
DOI: 10.1136/bmjno-2025-0014912025
Journal article
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
DOI: 10.1038/s41408-025-01236-62025
Journal article
Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort
DOI: 10.1016/j.bict.2025.1000202025
Journal article
ctDNA MRD after CAR-T
DOI: 10.1182/bloodadvances.20250175072025
Journal article
Long-lived IgE plasma cells persist in secondary lymphoid tissues using a navitoclax-sensitive survival program
DOI: 10.1016/j.immuni.2025.10.0062025
Conference Proceedings
Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.
DOI: 10.1182/blood-2025-2779